What is the recommended pre‑exposure prophylaxis (PrEP) regimen and timing before sexual activity?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

PrEP Prior to Sex: On-Demand (2-1-1) Dosing

For cisgender men having planned receptive anal sex, take 2 tablets of TDF/FTC 2-24 hours before sex, followed by 1 tablet 24 hours after the first dose, and another tablet 48 hours after the first dose 1.

Who Should Use On-Demand PrEP

On-demand (2-1-1) dosing is strongly recommended for cisgender men having planned receptive anal sex 1. This regimen can also be used by others having planned receptive anal sex (evidence rating: AIII), though the evidence is less robust 1.

Critical Limitation

On-demand PrEP is NOT appropriate for:

  • Receptive vaginal or neovaginal exposures (insufficient data) 1
  • Injection drug use exposures 1
  • People who cannot plan sexual activity in advance 2
  • Those having sex on more than 2 separate days per week 2

Exact Dosing Schedule

Single Sexual Event

  • 2 tablets: 2-24 hours before sex
  • 1 tablet: 24 hours after the first dose (i.e., 24 hours after taking the 2 tablets)
  • 1 tablet: 48 hours after the first dose (covering 48 hours after last sex) 1, 2

Multiple Sexual Events Within a Week

If sexual activity continues after the initial event, switch to daily single-tablet dosing until 2 doses are taken after the last sexual activity 1. If sex resumes within 7 days of the last dose, take only 1 tablet before sex. If more than 7 days have passed, restart with the full 2-tablet loading dose 2.

Special Population: Transgender Women on Hormone Therapy

Critical caveat: Transgender women using gender-affirming hormone therapy should take TDF/FTC with food when using 2-1-1 dosing 1. Rectal tissue concentrations of tenofovir-diphosphate (TFV-DP) may be lower early after starting 2-1-1 regimens in this population, which can be largely mitigated by taking the medication with food 1.

Alternative: Daily PrEP

For those who cannot plan sexual activity, have frequent sex (>2 days/week), or prefer simplicity, daily TDF/FTC is the alternative 1. Daily dosing should be initiated with a double dose followed by single daily tablets thereafter 1. When discontinuing daily PrEP, continue for 2 doses after last receptive anal sex or 7 days after last vaginal/neovaginal sex 1.

Recent data show that 4 or more doses per week on average provides high-level protection for both rectal and vaginal exposures, while 2 or more doses per week provides 79-88% reduction in HIV acquisition for rectal exposures 1.

Why This Matters

The 2025 International Antiviral Society-USA guidelines (published in JAMA) represent the most current, highest-quality evidence for PrEP dosing 1. On-demand dosing offers comparable efficacy to daily PrEP for cisgender men having receptive anal sex when used correctly, while reducing total drug exposure and potentially improving adherence for those with infrequent, planned sexual activity.

Common Pitfalls to Avoid

  • Don't use on-demand PrEP for vaginal exposures: The pharmacokinetics differ, and protective drug levels in vaginal tissue require longer lead time 1
  • Don't skip the post-sex doses: The 24-hour and 48-hour post-sex doses are essential for protection 1, 2
  • Don't use on-demand dosing if sex is unpredictable: Studies show only 24% of participants could anticipate sex >3 hours in advance 3, making daily PrEP more appropriate for many
  • Don't forget food with hormone therapy: This is a critical detail for transgender women that directly impacts drug levels 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.